European Academy of Allergy and Clinical Immunology

Alladapt Immunotherapeutics Announces Topline Pediatric Data from Phase 1/2 Harmony Study Evaluating ADP101 for the Treatment of Patients with Mono- and Multi-Food Allergy, as Presented at the European Academy of Allergy and Clinical Immunology Hybrid Con

Retrieved on: 
Tuesday, June 13, 2023
OIT, Encore, Therapy, Allergy, Food allergy, COVID-19, Adrenaline, Food, EAACI, European Academy of Allergy and Clinical Immunology, Trial of the century, Harmony, Milk, Patient, Physician, Anaphylaxis, Immunoglobulin E, FDA, Allergen, Safety, Conditional sentence, Pharmaceutical industry, Vaccine

MENLO PARK, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics, Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, today announced topline results from the Phase 1/2 Harmony study evaluating the efficacy and safety of ADP101 for the treatment of food allergy. The findings—which demonstrated dose-dependent, clinically meaningful responses, and a favorable safety and tolerability profile in pediatric patients with mono- and multi-food allergies—were presented in an oral session and a flash talk at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress June 9-11, 2023 in Hamburg, Germany.

Key Points: 
  • With this milestone, we are one step closer to our goal of delivering a pharmaceutical-grade, broadly applicable OIT to patients and providers.
  • The multiple allergen desensitization trends were broadly observed across foods and occurred in individual patients across unrelated food groups.
  • Epinephrine was primarily used for mild or moderate events and usage occurred with decreased frequency in the maintenance phase.
  • Food allergy is a largely invisible, chronic disease that places a severe immunological and psychological burden on patients and their families.

Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition

Retrieved on: 
Monday, June 12, 2023
Omalizumab, Asthma, Therapy, Allergy, Lirentelimab, EAACI, Atopic dermatitis, B cell, European Academy of Allergy and Clinical Immunology, SAN, Immunoglobulin E, Abstract, Vaccine

SAN CARLOS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023. The presentation highlighted preclinical data detailing lirentelimab and AK006 mechanism of action and inhibitory activity on IgE and non-IgE activated mast cells.

Key Points: 
  • The presentation highlighted preclinical data detailing lirentelimab and AK006 mechanism of action and inhibitory activity on IgE and non-IgE activated mast cells.
  • Omalizumab and remibrutinib have been shown to decrease IgE mediated mast cell activation and have shown activity in chronic spontaneous urticaria.
  • However, there are currently no therapeutics that selectively inhibit both IgE and non-IgE mediated mast cell activation.
  • The data presented today add to previous published preclinical data demonstrating that lirentelimab and AK006 inhibit multiple modes of mast activation.

KalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

Retrieved on: 
Monday, June 12, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Attack, University, Hereditary angioedema, OH, University of Cincinnati Academic Health Center, Pharmacokinetics, Medical school, EAACI, European Academy of Allergy and Clinical Immunology, HAE, Patient, University of Toronto, University of Cincinnati, Randomness, Division, ABC, St. Michael's Hospital, KALV, Immunology, Hospital, White, Safety, Pharmaceutical industry

KalVista is currently assessing sebetralstat as an oral, short-term prophylaxis in KONFIDENT-S, the two-year open-label extension study for the KONFIDENT phase 3 trial.

Key Points: 
  • KalVista is currently assessing sebetralstat as an oral, short-term prophylaxis in KONFIDENT-S, the two-year open-label extension study for the KONFIDENT phase 3 trial.
  • The first of these describes the persisting burden of HAE on patients in their attempt to live normally.
  • “We also see that even in the context of modern prophylaxis, there remains a significant persisting burden for people living with HAE.
  • These findings highlight gaps in the existing HAE treatments and potentially position sebetralstat to address these unmet needs in this therapeutic landscape.”

European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2023: Successfully Concludes, Setting New Milestones in Allergy and Clinical Immunology

Retrieved on: 
Monday, June 12, 2023
Urbanization, Allergy, Asthma, Drug, Prevalence, Food, EAACI, Atopic dermatitis, Global health, Research, Biomarker, History, Immunotherapy, Congress, European Academy of Allergy and Clinical Immunology, Climate change, Patient, Health, Social media, Pharmaceutical industry, Medical device

The EAACI Congress 2023 proved to be an exceptional event, featuring a wide array of sessions and activities that explored the forefront of allergy and immunology research.

Key Points: 
  • The EAACI Congress 2023 proved to be an exceptional event, featuring a wide array of sessions and activities that explored the forefront of allergy and immunology research.
  • Throughout the congress, participants engaged in in-depth discussions regarding the impact of environmental factors on allergic diseases.
  • Additionally, dedicated sessions focused on pediatric allergy and immunology ensured comprehensive discussions on the specific needs of young patients.
  • For more information and updates on the EAACI Annual Congress 2024 and other future events, please visit https://eaaci.org/events/ .

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Retrieved on: 
Sunday, June 11, 2023
Intellia Therapeutics, Plasma kallikrein, CRISPR, Hereditary angioedema, European Academy of Allergy and Clinical Immunology, HAE, NTLA, Therapy, EAACI, Patient, Pharmaceutical industry

NTLA-2002 is an in vivo, systemically administered CRISPR candidate being developed as a single-dose treatment for hereditary angioedema (HAE).

Key Points: 
  • NTLA-2002 is an in vivo, systemically administered CRISPR candidate being developed as a single-dose treatment for hereditary angioedema (HAE).
  • “After a single dose of our investigational CRISPR-based therapy, patients living with hereditary angioedema experienced durable elimination of their attacks.
  • “While early, these unprecedented interim data from the Phase 1 study continue to reinforce our belief that NTLA-2002 could be a potential functional cure for people with hereditary angioedema.
  • HAE attacks and plasma kallikrein protein levels will continue to be assessed through the end of the study.

Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Retrieved on: 
Saturday, June 10, 2023
Well, CSU, Survival, Quality of life, American Academy, Omalizumab, EAACI, B cell, European Academy of Allergy and Clinical Immunology, Angioedema, Hives, KIT, Patient, Swelling, Annual general meeting, AAAAI, UCT, Itch, Therapy, UAS7, Safety, Copper, Pharmaceutical industry, Palladium, Dermatology, Allergy

HAMPTON, N.J., June 10, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that updated data from the Company’s Phase 1b multi-dose clinical trial in chronic spontaneous urticaria (CSU) and new data from the Phase 1b single-dose cholinergic cohort included in the chronic inducible urticaria (CIndU) trial were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2023. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of mast cells. Data continue to support that mast cell depletion by barzolvolimab, as demonstrated by tryptase suppression, parallels symptom improvement.

Key Points: 
  • Data continue to support that mast cell depletion by barzolvolimab, as demonstrated by tryptase suppression, parallels symptom improvement.
  • In cholinergic urticaria, barzolvolimab again demonstrated remarkable response rates and impressive improvements in quality of life in this tough to treat form of inducible urticaria."
  • Celldex previously presented interim Phase 1b CSU data at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023.
  • At EAACI 2023, Celldex presented data on the complete 24 week experience for the 4.5 mg/kg cohort and data on angioedema impact across all study cohorts.

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

Retrieved on: 
Thursday, June 8, 2023
European Academy of Allergy and Clinical Immunology, Therapy, EAACI, CEST, EDT, Pharmaceutical industry

HAMPTON, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s barzolvolimab program will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2023 being held June 9-11 in Hamburg, Germany.

Key Points: 
  • HAMPTON, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s barzolvolimab program will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2023 being held June 9-11 in Hamburg, Germany.
  • Late Breaking Oral Presentation Number 000401: Barzolvolimab Demonstrates Clinical Activity in a Multiple Ascending Dose Trial in Chronic Spontaneous Urticaria
    Session Date & Time: Saturday, June 10, 2023, 12:00 - 1:00 pm CEST; 6:00 - 7:00 am EDT
    Session Date & Time: Saturday, June 10, 2023, 4:45 pm - 6:15 pm CEST; 10:45 am - 12:15 pm EDT

DBV Technologies to Participate in Upcoming EAACI Congress 2023

Retrieved on: 
Thursday, June 8, 2023
Asthma, Food allergy, Parent, Medical school, European Academy of Allergy and Clinical Immunology, Doctor of Philosophy, Peanut allergy, Science, EMA, Congress, DBV, IRCCS, Patient, Risk, Master of Science, DBV Technologies, FDA, Safety, Pharmaceutical industry, Residential care, Medical device, EAACI, Euronext, MD

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany.
  • DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall.
  • “We look forward to presenting the EPITOPE Phase 3 data at EAACI this year.
  • “Our symposium will address a theme that peanut-allergy caregivers know well: the burdens that patients face in living with their condition.

IgGenix Demonstrates Potential for an IgG4 Monoclonal Antibody-based Approach to Treating Peanut Allergy

Retrieved on: 
Friday, June 9, 2023
Health, Infectious Diseases, Health Technology, Clinical Trials, Research, Science, Biotechnology, Food allergy, Quality of life, EAACI, Antibody, Doctor of Philosophy, Congress, European Academy of Allergy and Clinical Immunology, Allergy, Epitope, Entrepreneurship, Immunoglobulin E, Allergen, Immunoglobulin G, Vaccine

IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to directly address allergic disease, today announced advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies.

Key Points: 
  • IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to directly address allergic disease, today announced advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies.
  • Nearly all peanut-specific IgE antibodies discovered from peanut-allergic individuals were high affinity, with many exhibiting double-digit picomolar affinity.
  • These IgG4 antibodies have the potential to form the basis of a therapeutic drug candidate exhibiting strong potency and efficacy in vitro, ex vivo, and in vivo.
  • “Peanut allergy is an increasingly prevalent unmet medical need that affects children and adults worldwide.

Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in Inhibition of Mast Cell Degranulation in Multiple Species at the European Academy of Allergy and Clinical Immunology

Retrieved on: 
Thursday, June 8, 2023
Research, Finance, FDA, Clinical Trials, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Science, MRGPRX2, Histamine, European Academy of Allergy and Clinical Immunology, Therapy, Drug discovery, Pharmaceutical industry, Vaccine

EP262 is a potent, highly selective antagonist of MRGPRX2 which inhibits agonist-induced mast cell degranulation and activation of the downstream inflammatory cascade, thus representing a novel therapeutic approach to a broad range of mast cell-mediated disorders.

Key Points: 
  • EP262 is a potent, highly selective antagonist of MRGPRX2 which inhibits agonist-induced mast cell degranulation and activation of the downstream inflammatory cascade, thus representing a novel therapeutic approach to a broad range of mast cell-mediated disorders.
  • The presentation highlights preclinical data demonstrating that treatment with EP262 potently attenuates mast cell degranulation and vascular permeability in vivo in a proprietary human MRGPRX2 transgenic mouse model.
  • In addition, EP262 was shown to block canine MRGPRX2-induced mast cell degranulation responses in Beagle dogs and to attenuate mast cell degranulation-induced histamine release in ex vivo human skin explants.
  • Details of the presentation are shown below:
    Presenter: Veena Viswanath PhD, Sr Vice-President Translational Biology and Drug Discovery, Escient Pharmaceuticals